HEMATOLOGY

Yi-Bin Chen, MD, reviews the case of a 50-year-old woman with steroid-refractory acute graft versus host disease (aGvHD) following allogeneic transplant and provides a discussion on treatment considerations for patients with aGvHD.

During a virtual Targeted Oncology Case-Based Roundtable, Ajai Chari, MD. a professor of Medicine, Hematology, and Medical Oncology at the Icahn School of Medicine at Mount Sinai in New York, NY, discussed the case of a 72-year-old patient with multiple myeloma.

The FDA has granted an accelerated approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.

Blinatumomab consolidation demonstrated significantly prolonged event-free survival in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia when compared with chemotherapy before allogeneic hematopoietic stem cell transplantation.

During a Targeted Oncology Case-Based Peer Perspectives event, Peter Hillmen, MBChB, PhD, discussed the case of 61-year-old patient with diffuse infiltration by chronic leukocytic leukemia.

The FDA has accepted a supplemental New Drug Application for ruxolitinib and granted it Priority Review as a potential treatment option for adult and pediatric patients 12 years and older with steroid-refractory chronic graft-versus-host disease.

Omidubicel was faster than standard myeloablative umbilical cord blood transplantation and correlated with promising clinical benefit, according to phase 3 data.

High rates of sustained MRD negativity were achieved with daratumumab-containing combinations compared with the standard-of-care combinations, according to an exploratory analysis of 2 ongoing clinical trials.

Ruxolitinib is one of only 2 treatments for MF that significantly improved the survival of patients. Still oncologists see opportunity to prolong survival in these patients even more.

The FDA has accepted a supplemental New Drug Application for zanubrutinib for the treatment of adult patients with Waldenström macroglobulinemia.

Early antitumor activity was seen with cord blood–derived natural killer immunotherapy in combination with high-dose chemotherapy and autologous stem cell transplant in patients with B-cell non-Hodgkin lymphoma, according to early results from a phase 2 trial.

In hematologic malignancies, a new class of molecules is emerging that may ultimately offer clinical benefits comparable to those chimeric antigen receptor T-cell therapies while reducing some of the negatives associated with them.

For the treatment of patients with newly diagnosed acute graft-versus-host disease, itolizumab has demonstrated promise in part A of the multicenter dose-ascending phase 1b/2 EQUATE study.

Results from the phase 3, randomized REACH3 trial further demonstrated the benefit of ruxolitinib over BAT in rates for failure-free survival, symptom improvement, and duration of response.

Data presented during the 2021 Transplantation and Cellular Therapy Meeting showed that treatment with Orca-T, achieved a significant reduction in cases of graft-versus-host disease and other impressive outcomes.

Results from 2 phase 3 clinical trials showed that use of the investigational gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients under the age of 18 years with transfusion-dependent beta-thalassemia.

Michael Bishop, MD, discusses the impact of chimeric antigen receptor T cell therapy across hematologic malignancies.

Ruxolitinib was found to be safe for utilization in children after a pediatric dosing algorithm was tested in patients with chronic graft-versus-host disease and induced responses.

A phase 1 study is the first to demonstrate that JSP191 is safe and effective in older patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome who are undergoing nonmyeloablative allogeneic hematopoietic cell transplantation.

In a pivotal phase 2 trial, administration of narsoplimab to patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy led to impressive responses and a favorable survival benefit.

Finding presented on patients with hematologic malignancies at the 2021 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR show that patients who had undergone a hematopoietic stem cell transplantation can accumulate effective immunity against SARS-CoV2 infection and non-SARS human coronaviruses.

The way I practice, personally, is that if they are older than 60 years, they are automatically high risk, and I will start hydroxyurea. In PV, being over 60 years and/or prior thrombosis automatically makes the patient high risk, so you should probably be starting a cytoreductive therapy.

Sagar Lonial, MD, FACP, summarizes current challenges and his hopes for the future concerning the treatment of multiple myeloma.

Sagar Lonial, MD, FACP, focuses on the treatment of multiple myeloma during the COVID-19 pandemic, discussing the standard of care with anti-CD38 monoclonal antibodies and daratumumab.

Sagar Lonial, MD, FACP, explains the importance of daratumumab/lenalidomide/low-dose dexamethasone (DRd) in several key areas, including progression-free survival versus common standard-of-care regimens in the PEGASUS trial, toxicities, and how active patients fare.